explore -WSS

explore

author：knowledge 2025-10-01 15:28:35 - browse：873

President Biden speaks on the Cancer Moonshot initiative at the John F. Kennedy Library in 2022. Evan Vucci/AP

WASHINGTON — The next chapter of President Biden’s moonshot to end cancer has landed. While the new goals are inspiring hope among cancer researchers, not everyone is impressed.

The president early Wednesday morning unveiled a slew of federal plans and private-sector agreements to fuel the relaunched Cancer Moonshot, a project to improve treatments and halve cancer deaths in the next 25 years. Among roughly 50 new programs and partnerships are multimillion-dollar pledges to advance testing, data pools, clinical trials and outreach efforts.

It is the latest phase of a project Biden first launched as vice president in the wake of his son Beau’s death from brain cancer in 2015. But while the first moonshot funneled money almost entirely to early-stage cancer research, its sequel is broadening efforts to prevent cancer deaths — particularly through anti-smoking efforts — and introduces a new focus on research infrastructure and patient engagement that some cancer researchers have applauded.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Hospitals look to new technology to keep health care workers safe

WSS

RaDonda Vaught links Vanderbilt hospital issues to patient death

Amid AI frenzy, a top HHS official's quest to create safeguards

FDA's Woodcock to retire early next year

Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

Congress must reauthorize a committee to support older Americans

hotspot

explore

hotspot

State Dept. review finds Biden bears some blame for Afghanistan failures

Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

Continuity nursing helped my family in our darkest PICU moments

As AI in medicine takes off, can 'human in the loop' prevent harm?

BioMarin wins approval for gene therapy to treat hemophilia A

Readout Newsletter: What is Casgevy? Does Wegovy hurt muscle?

In age of alternative facts, a scholarly course on calling out crap

Medicare coverage of Wegovy, once blocked, now looks possible

After affirmative action ruling, medical educators look to 'holistic review'

Amid AI frenzy, a top HHS official's quest to create safeguards

focus

Male and female sex labels in research insufficient, scientists say

A daunting task: navigating dual Medicare, Medicaid eligibility

FDA's Woodcock to retire early next year

John Green on his newest strategy for fighting tuberculosis

Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

Congress must reauthorize a committee to support older Americans

leisure time

knowledge

knowledge

focus